1. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
   L E Anselmino et al, 2021, Sci Rep CrossRef
2. A GLUT1 Inhibitor-Based Fluorogenic Probe for Warburg Effect-Targeted Drug Screening and Diagnostic Imaging of Hyperglycolytic Cancers
   Shunjie Zhang et al, 2021, Analytica Chimica Acta CrossRef
3. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
   Dey Nandini et al, 2021, Pharmaceuticals CrossRef
4. NIR Fluorescent Imaging and Photodynamic Therapy with a Novel Theranostic Phospholipid Probe for Triple-Negative Breast Cancer Cells
   Natalia I. Rubtsova et al, 2021, Bioconjugate Chem. CrossRef
5. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs.
   Qitong Wu et al, 2021, Cancers (Basel) CrossRef
6. An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer
   Narges Dastmalchi et al, 2021, Expert Review of Molecular Diagnostics CrossRef
7. Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human
   Weipeng Zhao et al, 2021, Front. Cell Dev. Biol. CrossRef
8. PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
   Wen-Jing Hsu et al, 2021, JPM CrossRef
9. Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer
   Fokhrul Hossain et al, 2021, Nutrients CrossRef
10. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
    Nayanendu Saha et al, 2022, Translational Oncology CrossRef
11. Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A
    Hung-Yu Lin et al, 2022, Biomedicine & Pharmacotherapy CrossRef
12. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer
    Diaaeldin M. Elimam et al, 2022, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
13. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
    Enrica Balza et al, 2022, Cancer Medicine CrossRef
14. Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells
    Yu-Ting Yen et al, 2021, IJMS CrossRef
15. Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules
    Rossana Galassi et al, 2022, Biomolecules CrossRef
16. Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes
    Christopher Wittmann et al, 2022, Inorg. Chem. CrossRef
17. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics
    Janice Jacson Mandumpala et al, 2022, Life Sciences CrossRef
18. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
    Frederic St-Denis-Bissonnette et al, 2022, Cancers CrossRef
19. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer
    Hagen Sjard Bachmann et al, 2022, Cancers CrossRef
20. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Ian Landry et al, 2022, Cureus CrossRef
21. Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
    Marta Marqués et al, 2022, Cancers CrossRef
22. Low-risk triple-negative breast cancers: clinico-pathological and molecular features
    Nicola Fusco et al, 2022, Critical Reviews in Oncology/Hematology CrossRef
23. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers
    Chi-Cheng Huang et al, 2022, Ann Surg Oncol CrossRef
24. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
    Ruoning Yang et al, 2022, Mol Biomed CrossRef
25. Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles
    Luis Exequiel Ibarra et al, 2022, Pharmaceutics CrossRef
26. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database
    Zhuowei Tang et al, 2022, Front. Endocrinol. CrossRef
27. The Value of Shear Wave Elastography in the Diagnosis of Breast Cancer Axillary Lymph Node Metastasis and Its Correlation With Molecular Classification of Breast Masses
    Changyun Luo et al, 2022, Front. Oncol. CrossRef
28. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
    Juan Carlos Montero et al, 2022, J Exp Clin Cancer Res CrossRef
29. Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics
    Amiya Das et al, 2022, ACAMC CrossRef
30. Cinobufacini Injection Inhibits the Proliferation of Triple-Negative Breast Cancer Through the Pin1–TAZ Signaling Pathway
    Lu Kong et al, 2022, Front. Pharmacol. CrossRef
31. The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis
    Yuyan Huang et al, 2022, Clin Exp Med CrossRef
32. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC
    Ha Rin Kim et al, 2022, Journal of Controlled Release CrossRef
33. Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
    Aiswarya Chaudhuri et al, 2022, Pharmaceuticals CrossRef
34. PD-L1 expression in Congolese women with triplenegative breast cancer
    Olivier Mukuku et al, 2022, JCPCR CrossRef
35. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Fei Yang et al, 2022, Bioorganic & Medicinal Chemistry CrossRef
36. Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape
    Xuemei Xie et al, 2022, Expert Opinion on Therapeutic Targets CrossRef
37. Prediction of Treatment Response in Triple Negative Breast Cancer From Whole Slide Images
    Peter Naylor et al, 2022, Front. Signal Process. CrossRef
38. Ceritinib is a novel triple negative breast cancer therapeutic agent
    Shengli Dong et al, 2022, Mol Cancer CrossRef
39. Discovery of novel acridine-chalcone hybrids with potent DNA binding and antiproliferative activity against MDA-MB-231 and MCF-7 cells
    Mária Vilková et al, 2022, Med Chem Res CrossRef
40. Surgical Efficacy and Prognosis of 54 Cases of Spinal Metastases from Breast Cancer
    Yao Weitao et al, 2022, World Neurosurgery CrossRef
41. Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression
    Hsin-Yi Chen et al, 2022, J Hematol Oncol CrossRef
42. Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Min Huang et al, 2022, Immunotherapy CrossRef
43. Coactosin-Like Protein in Breast Carcinoma: Friend or Foe?
    Bei Wang et al, 2022, JIR CrossRef
44. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    S. Michaleas et al, 2022, ESMO Open CrossRef
45. Association of Pathway Mutations With Survival in Taiwanese Breast Cancers
    Po-Sheng Yang et al, 2022, Front. Oncol. CrossRef
46. Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis
    Huilin Yang et al, 2022, Molecular Therapy CrossRef
47. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
    Fan Yang et al, 2022, Cell Biol Int CrossRef
48. Extracellular vesicles derived from Wharton’s Jelly mesenchymal stem cells inhibit the tumor environment via the miR-125b/HIF1α signaling pathway
    Yun-Hsuan Chang et al, 2022, Sci Rep CrossRef
49. Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
    Malvina Koni et al, 2022, Cancers CrossRef
50. LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells
    Li Pan et al, 2022, Biomedicines CrossRef
51. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
    Shengyu Pu et al, 2022, Front. Immunol. CrossRef
52. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
    Rita Ribeiro et al, 2022, Front. Mol. Biosci. CrossRef
53. Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
    Marek Z. Wojtukiewicz et al, 2022, Cancer Metastasis Rev CrossRef
54. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression
    Esraa Magdy Abdelraouf et al, 2022, Life Sciences CrossRef
55. 99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer
    Buhui Yu et al, 2022, Front. Bioeng. Biotechnol. CrossRef
56. The Present and Future of Clinical Management in Metastatic Breast Cancer
    Pauline H. Lin et al, 2022, JCM CrossRef
57. Isobavachalcone Induces Multiple Cell Death in Human Triple-Negative Breast Cancer MDA-MB-231 Cells
    Cheng-Zhu Wu et al, 2022, Molecules CrossRef
58. Platelet-Derived Extracellular Vesicles Stimulate Migration through Partial Remodelling of the Ca2+ Handling Machinery in MDA-MB-231 Breast Cancer Cells
    Mauro Vismara et al, 2022, Cells CrossRef
59. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming
    Hassan Yousefi et al, 2022, Oncogene CrossRef
60. Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer
    Yanhui Zhu et al, 2022, Cancer Medicine CrossRef
61. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer
    Xiaorui Sun et al, 2022, Front. Genet. CrossRef
62. Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrier
    Xin Liu et al, 2022, Clin Exp Metastasis CrossRef
63. Tumor-Derived Exosomes and Their Role in Breast Cancer Metastasis
    Shaojuan Huang et al, 2022, IJMS CrossRef
64. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
    Eva Kudelova et al, 2022, IJMS CrossRef
65. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair
    Shu-Ping Wang et al, 2021, Cell Death Dis CrossRef
66. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer
    Soyoung Kim et al, 2022, IJMS CrossRef
67. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
    Avinash Khadela et al, 2022, Med Oncol CrossRef
68. A Novel Prognostic Prediction Model Based on Pyroptosis-Related Clusters for Breast Cancer
    Baoxing Tian et al, 2022, JPM CrossRef
69. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
    Boya Lu et al, 2023, Technol Cancer Res Treat CrossRef
70. HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple‑negative breast cancer
    Mengdi Zhu et al, 2022, Oncol Lett CrossRef
71. Highly Metastatic Subpopulation of TNBC Cells Has Limited Iron Metabolism and Is a Target of Iron Chelators
    Yuze Wang et al, 2023, Cancers CrossRef
72. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling
    Yuqi Liang et al, 2023, DDDT CrossRef
73. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions
    Leilei Fu et al, 2023, Biochemical Pharmacology CrossRef
74. Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Jinlin Zhang et al, 2023, European Journal of Medicinal Chemistry CrossRef
75. Dysfunction of the ST7-AS1/miR-301b-3p/BTG1 ceRNA network promotes immune escape of triple-negative breast cancer
    Yong Li et al, 2023, International Immunopharmacology CrossRef
76. A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
    Xiangdi Meng et al, 2023, Front. Endocrinol. CrossRef
77. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: a preliminary study
    Sylwia Michlewska et al, 2023, International Journal of Pharmaceutics CrossRef
78. Eugenol modulates the NOD1-NF-κB signaling pathway via targeting NF-κB protein in triple-negative breast cancer cells
    Xiaoyu Shi et al, 2023, Front. Endocrinol. CrossRef
79. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer
    Jiamin Guo et al, 2023, Br J Cancer CrossRef
80. Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer
    Apsana Lamsal et al, 2023, Cell Commun Signal CrossRef
81. Anti-tumor potential and mode of action of karanjin against breast cancer; an in-silico approach
    Prarambh S R Dwivedi et al, 2023, Arabian Journal of Chemistry CrossRef
82. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer
    Radwa Y. Mekky et al, 2023, Translational Oncology CrossRef
83. Fluorouracil exacerbates alpha-crystallin B chain—mediated cell migration in triple-negative breast cancer cell lines
    Lili Yang et al, 2023, Sci Rep CrossRef
84. Icariin Induces Triple-Negative Breast Cancer Cell Apoptosis and Suppresses Invasion by Inhibiting the JNK/c-Jun Signaling Pathway
    Shenghan Gao et al, 2023, DDDT CrossRef
85. Based on immune checkpoint inhibitor to improve cancer treatment
    Yijin Chen, 2023, HSET CrossRef
86. The Effect of Berberine Follow by Blue Light Irradiation and Valproic Acid on the Growth Inhibition of MDA-MB-231 Breast Cancer Cells
    Mahdieh Meschi et al, 2023, Appl Biochem Biotechnol CrossRef
87. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
    Tomomi Sanomachi et al, 2023, Front. Oncol. CrossRef
88. The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications
    Zhuoya Jiao et al, 2023, Mol Diagn Ther CrossRef
89. The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
    Stefano Zapperi et al, 2023, IJMS CrossRef
90. DNAJB4 promotes triple-negative breast cancer cell apoptosis via activation of the Hippo signaling pathway
    Fang Fang et al, 2023, Discov Onc CrossRef
91. In silico de novo drug design of a therapeutic peptide inhibitor against UBE2C in breast cancer
    Andrea Mae Añonuevo et al, 2023, J. Bioinform. Comput. Biol. CrossRef
92. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
    Reza Mehdizadeh et al, 2023, Sci Rep CrossRef
93. Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer
    Zhiwen Xu et al, 2023, Sci. Transl. Med. CrossRef
94. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer
    Jiawen Bu et al, 2023, Nat Commun CrossRef
95. Antiproliferative effects of 13α/β-steroids on triple-negative MDA-MB-231 breast cancer cells: unraveling intracellular signaling without ERα
    Alexander M. Scherbakov et al, 2023, Braz. J. Pharm. Sci. CrossRef
96. Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
    Aiswarya Chaudhuri et al, 2023, Cancers CrossRef
97. A Carrier-Free Nanomedicine Enables Apoptosis-Ferroptosis Synergistic Breast Cancer Therapy by Targeting Subcellular Organelles
    Jiaxin Zhu et al, 2023, ACS Appl. Mater. Interfaces CrossRef
98. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study
    Wei Fan et al, 2023, Tohoku J. Exp. Med. CrossRef
99. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy
    Richard W DeClue et al, 2023, Future Oncology CrossRef
100. Nonmonotone invasion landscape by noise-aware control of metastasis activator levels
     Yiming Wan et al, 2023, Nat Chem Biol CrossRef